Preview

Медицинский Совет

Расширенный поиск

Некоторые аспекты лекарственной и нелекарственной терапии болезни Альцгеймера

https://doi.org/10.21518/2079-701X-2015-2-6-9

Полный текст:

Аннотация

В статье представлен современный подход к лечению пациентов с болезнью Альцгеймера (БА). Приводятся данные по изучению эффективности антагониста глутаматных NMDA-рецепторов меман-тина при БА, влияния мемантина на когнитивный дефицит, поведенческие симптомы и повседневную активность больных.

Об авторах

О. В. Котова
Первый Московский государственный медицинский университет им. И.М. Сеченова
Россия


Е. С. Акарачкова
Первый Московский государственный медицинский университет им. И.М. Сеченова
Россия


Список литературы

1. De-Paula VJ, Radanovic M, Diniz BS, Forlenza OV. Alzheimer's disease. Subcell Biochem., 2012, 65: 329-52. doi: 10.1007/978-94-007-5416-4_14.

2. Ashford JW, Schmitt FA, Kumar V. Diagnosis of Alzheimer's disease. Psychiatr Ann, 1998, 26: 262-8.

3. Livingston G, Katona C, Roch B et al. A dependency model for patients with Alzheimer's disease: its validation and relationship to the costs of care - the LASER-AD Study. Curr Med Res Opin, 2004, S7: 1007-16.

4. Cummings JL, Cole G. Alzheimer disease. JAMA, 2002, 287: 2335-8.

5. Reisberg B, Burns A, Brodaty H, et al. Diagnosis of Alzheimer's disease. Report of an International Psychogeriatric Association Special Meeting Work Group under the co-sponsorship of Alzheimer's Disease International, the European Federation of Neurological Societies, the World Health Organization, and the World Psychiatric Association. Int Psychogeriatr, 1997, 9 (Suppl. 1): 11-38.

6. Hebert LE, Scherr PA, Bienias JL, et al. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol, 2003, 60: 1119-22.

7. Fratiglioni L, De Ronchi D, Aguero-Torres H. Worldwide prevalence and incidence of dementia. Drugs Aging, 1999, 15: 365-75.

8. Singh B, Parsaik AK, Mielke MM, Erwin PJ, Knopman DS, Petersen RC5, Roberts RO. Association of mediterranean diet with mild cognitive impairment and Alzheimer's disease: a systematic review and meta-analysis. J Alzheimers Dis., 2014, 39(2): 271-82. doi: 10.3233/JAD-130830.

9. Abbott A. Dementia: a problem of our age. Nature, 2011, 475(7355): 2-4.

10. Nicolia V, Lucarelli M, Fuso A. Environment, epi-genetics and neurodegeneration: Focus on nutrition in Alzheimer's disease. Exp Gerontol., 2014, Oct. 14. pii: S0531-5565(14)00281-2. doi: 10.1016/j. exger.2014.10.006.

11. Williams PT. Lower Risk of Alzheimer's Disease Mortality with Exercise, Statin, and Fruit Intake. J Alzheimers Dis., 2014, Nov. 14 [Epub ahead of print].

12. Herrmann N, Chau SA, Kircanski I, Lanctot KL. Current and emerging drug treatment options for Alzheimer's disease: a systemic review. Drugs, 2011, 71(15): 2031-2065.

13. Villanueva G, Lopez de Argumedo M, Elizondo I. Dementia drug consumption in the Basque Country between 2006 and 2011. Neurologia, 2014, Nov. 11. pii: S0213-4853(14)00202-3. doi: 10.1016/j. nrl.2014.09.006.

14. Shimizu E, Tang YP, Rampon C, Tsien JZ, NMDA receptor-dependent synaptic reinforcement is a crucial process for memory consolidation. Science, 2000, 290: 1170-74.

15. Marvanova M, Lakso M, Pirhonen J et al. E. The neuroprotective agent memantine induces brain-derived neurotrophic factor and trkB receptor expression in rat brain. Mol. Cel. Neurosci., 2001, 18 (3): 247-258.

16. Van Dyck CH, Schmitt FA, Olin JT. A responder analysis of memantine treatment in patients in Alzheimer disease maintained on donepezil. Am J Geriatr Psychiatry, 2006, 14: 428-37.

17. Blesa R. Clinical Experience of Memantine in Alzheimer's Disease. European Neurological Review, 2008, 3(2): 22-27.

18. Peskind ER, Potkin SG, Pomara N et al. Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. Am J Geriatr Psychiatry, 2006, 14: 704-15.

19. Bullock R. The needs of the caregiver in the long-term treatment of Alzheimer disease. Alzheimer Dis Assoc Disord, 2004, 18: 17-23.

20. Cummings JL, Mega M, Gray K et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology, 1994, 44: 2308-14.

21. Gauthier S, Wirth Y, Mobius H-J. Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised controlled trials. Int J Geriatr Psychiatry, 2005, 20: 459-64.

22. Wilcock GK, Ballard CG, Cooper JA, Loft H. Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies. J Clin Psychiatry, 2008, Mar., 69(3): 341-8.

23. Schneider LS, Tariot PN, Dagerman KS et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med, 2006, 355: 1525-38.

24. Rive B, Vercelletto M, Damier FD, Cochran J, Francois C. Memantine enhances autonomy in moderate to severe Alzheimer's disease. Int J Geriatr Psychiatry, 2004, May, 19(5): 458-64.

25. Wimo A, Winblad B, Stoffler A et al. Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease. Pharmacoeconomics, 2003, 21: 327-40.

26. Wenk GL, Quack G, Mobius H-J et al. No interaction of memantine with acetylcholinesterase inhibitors approved for clinical use. Life Sci, 2000, 66: 1079-83.

27. Tariot PN. Medical management of advanced dementia. J Am Geriatr Soc, 2003, 51: 305-13.


Просмотров: 135


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2079-701X (Print)
ISSN 2658-5790 (Online)